key: cord-0274917-cqagl2no
authors: Hingankar, Nitin; Deshpande, Suprit; Das, Payel; Rizvi, Zaigham Abbas; Burns, Alison; Barman, Shawn; Zhao, Fangzhu; Ansari, Mohammed Yousuf; Mukherjee, Sohini; Torres, Jonathan L.; Chattopadhyay, Souvick; Mehdi, Farha; Sutar, Jyoti; Rathore, Deepak Kumar; Pargai, Kamal; Singh, Janmejay; Sonar, Sudipta; Jakhar, Kamini; Bhattacharyya, Sankar; Mani, Shailendra; Singh, Savita; Dandotiya, Jyotsna; Kshetrapal, Pallavi; Thiruvengadam, Ramachandran; Batra, Gaurav; Medigeshi, Guruprasad; Ward, Andrew B.; Bhatnagar, Shinjini; Awasthi, Amit; Sok, Devin; Bhattacharya, Jayanta
title: A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant
date: 2021-12-27
journal: bioRxiv
DOI: 10.1101/2021.12.25.474152
sha: 73590e6c99ca123909fdc3a084325b62e3c1fca9
doc_id: 274917
cord_uid: cqagl2no

Although efficacious vaccines have significantly reduced the morbidity and mortality due to COVID-19, there remains an unmet medical need for treatment options, which monoclonal antibodies (mAbs) can potentially fill. This unmet need is exacerbated by the emergence and spread of SARS-CoV-2 variants of concern (VOCs) that have shown some resistance to vaccine responses. Here we report the isolation of two highly potently neutralizing mAbs (THSC20.HVTR04 and THSC20.HVTR26) from an Indian convalescent donor, that neutralize SARS-CoV-2 VOCs at picomolar concentrations including the delta variant (B.1.617.2). These two mAbs target non-overlapping epitopes on the receptor-binding domain (RBD) of the spike protein thereby preventing the virus attachment to its host receptor, human angiotensin converting enzyme-2 (hACE2). Furthermore, the mAb cocktail demonstrated protection against the Delta variant at low antibody doses when passively administered in the K18 hACE2 transgenic mice model, highlighting their potential as cocktail for prophylactic and therapeutic applications. Developing the capacity to rapidly discover and develop mAbs effective against highly transmissible pathogens like coronaviruses at a local level, especially in a low- and middle-income country (LMIC) such as India, will enable prompt responses to future pandemics as an important component of global pandemic preparedness. Highlights Identification of an Indian convalescent donor prior to emergence of SARS-CoV-2 Delta variant whose plasma demonstrated neutralization breadth across SARS-CoV-2 variants of concern (VOCs). Two (THSC20.HVTR04 and THSC20.HVTR26) monoclonal antibodies isolated from peripheral memory B cells potently neutralize SARS-CoV-2 VOCs: Alpha, Beta, Gamma, Delta and VOIs: Kappa and Delta Plus. THSC20.HVTR04 and THSC20.HVTR26 target non-competing epitopes on the receptor binding domain (RBD) and represent distinct germline lineages. Passive transfer of THSC20.HVTR04 and THSC20.HVTR26 mAbs demonstrated protection against Delta virus challenge in K18-hACE2 mice at low antibody doses. Graphical Abstract

Introduction SARS-CoV-2 is a positive-sense single stranded RNA virus that is the etiologic cause of COVID-19, which 14 has led to over 5 million deaths globally (https://covid19.who.int/). Although SARS-CoV-2 has a relatively low 15 mutation rate, a combination of high transmission events (over 250 million cases to date), inequitable vaccine access, 16 and prevailing vaccine hesitancy has led to the selection and spread of variants of concern (VOCs) that drive the 17 persisting pandemic. These VOCs (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/) have 18 garnered mutations that give them a selective advantage, either higher transmission, resistance to vaccine responses, 19

or both. Among all the SARS-CoV-2 VOCs, the Delta variant (B.1.617.2), first detected in India in late 2020 in the 20 state of Maharashtra Mlcochova et al., 2021) , has become the globally dominant circulating strain 21 and accounts for >85% sequences reported globally (https://nextstrain.org/ncov/gisaid/global). The Delta variant led 22

to a large spike in COVID-19 cases in India as part of a second wave that culminated in over 30 million cases and 23 over 400,000 deaths (Mlcochova et al., 2021; Thiruvengadam et al., 2021a) . Since the first case of Delta was reported, 24

scientists have determined that the Delta variant is more than twice as transmissible as the original strain of SARS-25

CoV-2 . Some studies have also indicated that infection with the Delta variant leads to higher viral 26 loads and worse disease prognosis compared the original Wuhan strain (Teyssou et al., 2021) . Importantly, countries 27 with high vaccination rates observed increases in cases due to Delta, indicating some breakthrough infection, but did 28 not observe a proportional increase in hospitalization (Bergwerk et al., 2021; Lopez Bernal et al., 2021) . 29

Unfortunately, countries with limited access to vaccines face higher rates of COVID-19 cases and increases in 30 hospitalization, which could overwhelm health systems and add to the growing tally of morbidity and mortality due 31

to Since the emergence of Delta, a new SARS-CoV-2 variant called Omicron has captured the attention of 33 scientists and public health officials. Omicron contains a much larger number of mutations than Delta when compared 34 to the original strain. Early studies have indicated that Omicron is four times more transmissible than the Delta variant 35 and studies are underway on whether vaccine responses are less effective against Omicron and whether Omicron 36 infection increases the risk for severe COVID-19 disease. As access to and uptake of efficacious vaccines remain 37 inequitable across the globe, the likelihood of additional VOCs emerging is high, particularly among 38 analysis showed RBD binding affinity (KD) of these five mAbs for RBD ranging from KD values between 0.19-117 0.813 nM, with THSC20.HVTR04 having the highest affinity (0.19 nM) and THSC20.HVTR39 having the lowest 118 affinity (0.813 nM). These values closely match apparent affinity measurements by ELISA to RBD with EC50 values 119 ranging from 0.19-0.06 µg/mL ( Figure S3B ). THSC20.HVTR04 and THSC20.HVTR26 showed the highest affinity 120 in these assays. 121

Since we used monomeric RBD to isolate the mAbs, we further assessed the ability of the isolated mAbs to 122 bind to trimeric spike protein expressed on the cell surface. For this purpose, we expressed the SARS-CoV-2 spikes 123

representing Wuhan wild-type or Kappa (B.1.617.1) variant on the surface of 293T cells and measured binding of 124 mAbs to cell surface spike by fluorescence-activated cell sorting (FACS) . As shown in Figure 2B , THSC20.HVTR04 125 and THSC20.HVTR26 bound more strongly than the other mAbs to the spike proteins expressed on the surface of 126

We next evaluated all of the mAbs for neutralization activity against SARS-CoV-2 variants in a pseudovirus 128 assay. The panel of SARS-CoV-2 variants included the Wuhan strain, Alpha, Beta and Kappa strains. We found that 129 THSC20.HVTR04 and THSC20.HVTR26 neutralized these SARS-CoV-2 variants with the highest potency ( Figure  130   S4 ). This observation is consistent with their high binding affinity to RBD as shown above. Additionally, we observed 131 that mAb THSC20.HVTR39 neutralized SARS-CoV with IC50 of 2.9 µg/mL, indicating that this particular mAb is 132 capable of neutralizing both SARS-CoV and SARS-CoV-2. 133

Since, THSC20.HVTR04 and THSC20.HVTR26 showed the greatest potency out of all the isolated mAbs, 134 these were subsequently evaluated for neutralization individually and in combination in live virus focus reduction 135 neutralization assay against the following VOC isolates: Alpha, Beta, Delta and VOI Kappa (as shown in Figure 2C  136 and Figure S5 ). We also compared these antibodies to previously reported neutralizing mAbs against in a 137 pseudovirus neutralization assay ( Figure 2D ). As shown in Figure 2C and Table S3 , both THSC20.HVTR04 and 138 THSC20.HVTR26 mAbs showed very potent neutralization of all the VOCs and the Kappa variant with IC50s 139 ranging from 0.003-0.01 µg/mL when assessed against live virus isolates. Comparable neutralization potencies of 140 THSC20.HVTR04 and THSC20.HVTR26 mAbs individually and in combination were also observed when assessed 141 in pseudovirus neutralization assay ( Figure 2D and Table S4 ). Both THSC20.HVTR04 and THSC20.HVTR26 142 mAbs potently neutralize Gamma (P1) and Delta-plus variants in the pseudovirus neutralization assay, which are 143 resistant to some of the previously reported neutralizing mAbs. We note the modest superiority of these two novel 144 mAbs over REGN10933 and REGN10987 mAbs when compared head to head in the same pseudovirus neutralization 145 assay. Taken together, our data report the discovery of two highly potent mAbs (THSC20.HVTR04 and 146 THSC20.HVTR26) from a single convalescent donor that not only bind to RBD with high affinities but also are 147 capable of potently neutralizing all the VOCs and VOIs tested in this study. 148 149 Neutralizing antibodies from the same donor target non-competing epitopes on RBD. 150

To assess the epitope specificities of the newly isolated mAbs on SARS-CoV-2 RBD, we performed epitope 151 binning using biolayer interferometry as described previously (Rogers et al., 2020) . To achieve this, biotinylated 152 RBD was first loaded on the streptavidin biosensor followed by binding of saturating mAb at a high concentration 153 (100 µg/mL). Subsequently, binding of a competing mAb at lower concentration (25 µg/mL) to RBD was evaluated 154

in the presence of saturating mAb. We also tested four previously reported anti-SARS-CoV-2 antibodies (CC12.1, 155 CC12.3, CC12.18 and CC6.33.1) (Rogers et al., 2020) that target two distinct epitopes on RBD to inform our epitope 156 binning. Our data revealed two distinct non-overlapping epitopes for THSC20.HVTR04 and THSC20-HVTR26 on 157 the RBD. THSC20.HVTR06 and THSC20.HVTR39 did not compete with THSC20.HVTR-04 and THSC20-HVTR-158 26, indicating distinct epitope specificities for these mAbs ( Figure 3A ). The epitope binning experiment also revealed 159 that THSC20.HVTR-88 and THSC20.HVTR04 have similar or overlapping epitope specificities. Compared to 160 previously reported antibodies, our experimental data show similar epitope specificities between THSC20.HVTR04 161 and CC6.33.1 (RBD-B) as well as THSC20.HVTR26 and CC12.1 (RBD-A). 162

We next examined whether the isolated monoclonal antibodies compete with RBD for ACE2 receptor 163 binding. We carried out mAb-RBD competition for ACE2 binding assay by first incubating mAbs with RBD in a 4:1 164 ratio and subsequently measured binding to HeLa-ACE2 target cells by FACS. As shown in Figure 3B , among all 165 the mAbs tested, THSC20.HVTR04 and THSC20.HVTR26 effectively blocked RBD binding to ACE2. We next 166 determined which residues in the receptor binding motif (RBM) are required for antibody neutralization (Baum et 167 al., 2020; Greaney et al., 2021; Harvey et al., 2021) for THSC20.HVTR04 and THSC20.HVTR26. We found that 168 mutations N439K, N440K and K444N resulted in reduced sensitivity to THSC20.HVTR04, with N439K 169 demonstrating greater than a 160-fold reduction in neutralization when assessed in pseudovirus neutralization assay 170 (Table S4) . Meanwhile, the neutralization activity of THSC20.HVTR26 was unaffected by any of these point 171 substitutions. These data suggest that THSC20.HVTR04 might have reduced sensitivity to the Omicron variant while 172 THSC20.HVTR26 might retain neutralization activity, both of which need to be verified experimentally. 173

To further characterize the epitope specificities of these antibodies, we analyzed binding of the mAbs to full 174 length spike by negative stain electron microscopy (NS-EM). Briefly, purified IgG Fab fragments of both 175 THSC20.HVTR04 and THSC20.HVTR26 were incubated with the trimeric spike and mAb-spike complexes were 176 further purified by SEC as described above. Analysis of 2D class averages ( Figure S6 ) and further 3D refinements 177 of EM structural data indicated that THSC20.HVTR04 mAb binds to RBD in the up-conformation, whereas 178 THSC20.HVTR26 can bind to RBD in different stoichiometries both in the "up" and "down" RBD conformation on 179 the spike ( Figure 3C ). NS-EM data also showed full occupancy of the three RBD protomers on trimer spike for 180 THSC20.HVTR26. 181 182 THSC20.HVTR04 and THSC20.HVTR26 combination protects against Delta challenge in K18 hACE-2 mice. 183

Based on their ability to neutralize all the SARS-CoV-2 variants with highest potency, we selected 184 THSC20.HVTR04 and THSC20.HVTR26 to assess protection efficacy against Wuhan and Delta variant challenge 185 in a K18-human ACE2 (hACE2) transgenic mice model (Winkler et al., 2020) . Moreover, both these mAbs were 186 negative in an ELISA-based polyreactivity assay with solubilized CHO membrane proteins ( Figure S7 ), further 187 supporting their suitability for assessing their protective efficacy in the animal model. The experimental design of 188 the efficacy assessment in K18-hACE2 transgenic mice model is shown in Figure 4A and Figure and were subsequently challenged intranasally with 10 5 plaque forming units (PFUs) / mice of SARS-CoV-2 (Wuhan 194 isolate) 24 hours after antibody administration. Prior to virus challenge, we obtained blood samples to determine 195 serum IgG titers. The changes in body weight for all the experimental animals was measured daily until day 6 (end-196 point) ( Figure 4B ). Additional clinical parameters were monitored to determine overall disease severity index at day 197 6-7 post challenge. All the mice were sacrificed on day 6 and lung tissues were harvested to measure lung virus load. 198 As shown in Figure 4B , mice in the groups 2 (infection control) and 3 (non SARS-CoV-2 specific IgG control) 199 exhibited significant weight loss of more than 10% on day 6 compared to those groups that received neutralizing 200 antibodies. Moreover, mice that received neutralizing antibodies showed near undetectable viral RNA loads in their 201 lung compared to the virus challenge group (group 2) the isotype control group (group 3) (P<0.001) ( Figure 4C) . 202

We observed a strong correlation (P<0.0001) between minimal weight loss and undetectable lung virus load in the 203 mice that received neutralizing antibodies ( Figure 4D ). 204

To further assess whether these two mAbs could also demonstrate protection against the more virulent Delta 205 (B.1.617.2) variant, we repeated the same strategy as described above. For this, we arranged the mice into seven 206 groups ( Figure S8D ) and titrated the combination of neutralizing antibodies from 10 mg/kg (equivalent to 200 µg 207 per animal) to 0.156 mg/kg body weight (equivalent to 3.125µg per animal) through four-fold serial dilutions. The 208 results are comparable to the Wuhan challenge experiment (Figures 4E-G and Figure S8 ) -all the mice in the 209 infection control group (group 2) and the isotype control group (group 3) exhibited significant weight loss at day 6, 210 whereas no significant weight loss was observed in animals those received the antibody cocktail including those 211 receiving the lowest dose (0.156 mg/kg body weight; group 7) ( Figure 4E ). In addition, as an indicator of clinical 212 prognosis, we measured lung viral RNA at day 6 and found significant reduction in the lung viral load even at an 213 antibody dose as low as 0.625mg/kg body weight (P<0.001) ( Figure 4F ). Interestingly, we observed near 2-fold 214 lower lung virus load in animals those received the lowest dose of the mAb cocktail (0.156 mg/kg body weight; 215 group 7). As expected, a strong correlation between minimal or no loss in body weight and undetectable lung virus 216 load in the mice that received different doses of mAb combination was observed ( Figure 4G and Figure S8F) . 217

Taken together our study demonstrated protection by a combination of these two potently neutralizing mAbs against 218 the highly virulent Delta variant in a transgenic hACE-2 mice model. 219

Establishing antibody discovery capacity in low and middle-income countries (LMICs) is a key component 220 of pandemic preparedness to enable prompt responses to emerging global health challenges. The likelihood of new 221 virus variants emerging in LMIC is high as access to vaccines and treatment options are delayed or limited and where 222 there is an abundance of comorbidities that could accelerate the selection of new VOCs. Hence, enabling the 223 discovery and development of monoclonal antibodies at the local level will provide new countermeasures that can 224 be developed as treatment or prevention options that meet local needs while access to other interventions remain 225

In our present study, we characterized mAbs that were isolated from an Indian convalescent donor in 2020 227 before the emergence of the deadly Delta variant. Among these mAbs, two (THSC20.HVTR04 and 228 THSC20.HVTR26) showed neutralization of Alpha, Beta, Gamma and Delta VOCs and other VOIs including Kappa 229

and Delta-Plus variants that originated in India. This pair of nAbs target non-competing epitopes on RBD and 230 competed with RBD for binding to the ACE2 receptor on target cells. For THSC20.HVTR04, we identified residues 231 N439, N440 and K444 within the RBM as critical for antibody neutralization. We did not observe point substitutions 232 that affected the neutralization potency of THSC20.HVTR26 mAb. Of note, the ability of THSC20.HVTR04 to 233 potently neutralize all the VOCs could be explained by the fact that none of them possess mutations at amino acid 234 positions N439, N440 and K444 (Tao et al., 2021) . Reduction in neutralization sensitivity of SARS-CoV-2 with 235 N440K by THSC20.HVTR04 as observed in our present study indicate that recently emerged Omicron variant of 236 SARS-CoV-2 may likely be resistant to neutralization by THSC20.HVTR04 but not by THSC20.HVTR26. Indeed, 237 it will be important to precisely map and validate key epitope contacts for both THSC20.HVTR04 and 238 THSC20.HVTR26 by structural studies. Our negative stain EM studies also suggest that both the mAbs binds at 239 RBM of the RBD on viral spike, although distinctly. THSC20.HVTR04 binds RBD in the up conformation only 240 while THSC20.HVTR26 binds to the RBD in both up and down conformations. Different classes of mAbs targeting 241 RBD have been reported such as RBM-I, RBM-II, RBM-III and RBD core cluster I and cluster II (Finkelstein et al., 242 2021) . Based on these observations and recent structural analyses of the variety of SARS-CoV-2 mAbs we can 243 classify THSC20.HVTR04 in the RBM class I and THSC20.HVTR26 in the RBM class II (Finkelstein et al., 2021) . 244

Although we do not have high-resolution structural data in the present study, it is possible that our mAbs bind to 245 their epitopes using an angle of approach and geometries that may be distinct than other potent mAbs in clinical use 246 although they compete for the same epitope region. 247

To evaluate in vivo activity, we assessed the prophylactic efficacy of our two best mAbs (THSC20.HVTR04 248 and THSC20.HVTR26) individually as well as in combination using an established model of SARS-CoV-2 infection 249 in hACE2-expressing K18 transgenic mice (Winkler et al., 2020) . Mice injected with THSC20-HVTR-04 or 250 THSC20-HVTR-26 mAbs one day before Wuhan and Delta virus challenge were completely protected from weight 251 loss and exhibited significant decrease in lung viral load compared to mice that were given HIV-1 mAb Our findings suggest that these two mAbs are valuable additions to the arsenal of existing potent mAbs 259 against SARS-CoV-2 for development. The lessons learned from the unprecedented SARS-CoV-2 pandemic 260 highlight the utility of timely response to such pandemics through discovery of effective mAbs against viral 261 pathogens as one of the components of pandemic preparedness for combating coronaviruses and other deadly viruses. 262

In the present scenario it is of paramount importance to promote and build capacity at LMICs to rapidly discover 263 neutralizing mAbs against viral and other pathogens which will enable us to respond promptly to existing and future 264 pandemics of coronaviruses or other highly transmissible viral pathogens. 

We acknowledge the Department of Biotechnology Consortium for COVID-19 Research and all the consortium 292 partners for making this study possible. We also thank the study participants for the clinical specimens following 293 ethical guidelines. We thank all the staff members of our laboratories, THSTI Biorepository, THSTI Data Table S1 . Convalescent donor history & background information. Table 2 . Heavy and light chain variable IgG sequence characteristics and germline usages. Table S3 . Neutralization potency of THSC20.HVTR04 and THSC20.HVTR26 and their combination against replication competent SARS-CoV-2 live VOCs. Table S4 . Neutralization breadth and potency of THSC20.HVTR04 and THSC20.HVTR26 and their combination against pseudoviruses expressing different SARS-CoV-2 VOC and VOI spike variants. Table S5 . Effect of key point mutations within RBM in SARS-CoV-2 spike on neutralization potency of THSC20.HVTR04 and THSC20.HVTR26 mAbs. Figure S1 . Representative Gating Strategy for the Antigen (RBD)-specific B cell sorting. Peripheral blood mononuclear cells (PBMCs) obtained from a convalescent donor C-03-0020 were stained with conjugated antibodies to cell surface markers, streptavidin labelled RBD probes and live dead stain and RBD-specific single B cells were sorted using a flow sorter. Singlet living CD19 + C20 + IgG + cells were gated and cells with positive SARS-CoV-2 RBD staining were selected for the single cell sorting into the 96 well plate prefilled with lysis buffer. 

Low resolution images of the SEC purified complex of THSC20.HVTR04 and THSC20.HVTR26 Fabs with SARS-CoV-2 spike protein which were subsequently used for further refinement to generate high-resolution image as shown in Figure 3C . 

The participants included in this study were members of DBT COVID-19 consortium cohort, organised by 

Antigen-specific single memory B cell sorting was performed in a FACS sorter (BD FACS Melody) essentially 377 following the methods as described earlier (Rogers et al., 2020) . Briefly, cryo-preserved PBMCs were first thawed 378 at 37 º C in a water bath and washed with an RPMI medium containing 10% fetal bovine sera (FBS) following 379 incubation with fluorescently-labeled antibodies (BD Biosciences) against cell surface markers for CD3 (PE-Cy7); 380 CD8 (PE-Cy7); CD14(PE-Cy7); CD16 (PE-Cy7); CD19 (BV421); CD19 (BV421); IgD (PerCP-Cy5.5); IgG (APC-381 H7) in addition to labelled RBD as an antigen in FACS buffer containing PBS (pH7.4), 1% FBS, and 1.0 mM EDTA 382 on ice. Live/Dead Fixable Aqua Blue Cell Stain (Thermo Fisher Inc.) was used to stain the cells for another 10 383 minutes on ice as per the manufacturer's instructions. The avi-tagged SARS-CoV-2 RBD antigen was first labeled 384 with biotin (Avidity, BirA500) was subsequently coupled to streptavidin-PE and streptavidin-APC (BD Biosciences) 385 by incubating the mixture at 4 º C for 1 hour at 4:1 molar ratio. The stained cells were subsequently washed with FACS 386 buffer to remove unbound antibodies and probe and then filtered through 70-μm cell mesh (BD Biosciences) before 387 processed in the FACS sorter. Single antigen RBD + CD3 -CD8 -CD14 -CD16 -CD19 + CD20 + IgD -IgG + cells were sorted 388 and collected into individual wells of a 96-well plate pre-filled with 20 ul of lysis buffer containing reverse 389 transcriptase buffer (Thermo Fisher), IGEPAL (Sigma), DTT and RNAseOUT (Thermo Fisher). Plates containing 390 sorted cells were sealed, snap-frozen on dry ice and stored at -80°C until used further. 391 392

cDNA Superscript III Reverse Transcription kit (Thermo Fisher) was used to prepare from sorted cells, cDNA master 394 mix containing dNTPs, random hexamers, IgG gene-specific primers and RT enzyme was added to generate cDNA. 395

Heavy and light-chain variable regions of IgG were amplified in independent nested PCR reactions using specific 396 primers. First round PCR amplification was performed using HotStar Taq DNA Polymerases (Qiagen) and second 397 round nested PCR was performed using Phusion HF DNA polymerase (Thermo Fisher Inc.). Specific restriction 398 enzyme cutting sites (heavy chain, 5′-AgeI/3′-SalI; kappa chain, 5′-AgeI/3′-BsiWI; and lambda chain, 5′-AgeI/3′-399 XhoI) were introduced in the second round PCR primers in order to clone into the respective expression vectors. 400

Amplified PCR products were verified on the agarose gel and wells with double positives (with amplification of both 401

Heavy and Light chain variable regions from the same well) were identified and selected for subsequent cloning 402 experiments. PCR products were digested with specific restriction enzymes, purified and cloned in-frame into 403 expression vectors encoding the human IgG1, Ig kappa or Ig lambda constant domains using the Quick Ligase cloning 404 system (New England BioLabs) according to the manufacturer instructions. Ligation reactions were transformed into 405 NEB 5-alpha competent E. coli cells, plated on LB agar plates containing ampicillin and incubated overnight at 37oC 406 in the incubator. Colonies with desired inserts were screened by colony PCR and used for preparation of plasmid 407 DNA. Plasmid clones with correct insert were further confirmed by restriction digestion with respective (New 408 England Biolabs, Inc.) restriction enzymes before being selected for the subsequent transfection experiment. 409

Confirmed heavy and light chain plasmid DNA were co-transfected in 293T cells (ATCC) using Fugene transfection 410 reagent (Promega) in 24 well plates for preparing antibody supernatant for initial screening for their expression and 411 antigen specificity as detailed in the following section. Sanger sequencing were carried out to obtain the nucleotide 412 and amino acid sequences of variable heavy and light IgG chains. Analysis of mAb sequences were carried out using 413 the IMGT (www.imgt.org) V-quest webserver tool. ELISA plate (Thermo Fisher Scientific Inc.) and incubated overnight at 4°C. Next day after washing, plates were 429 blocked with 3% BSA in PBS (pH 7.4) for 1 hour at room temperature. 2 μg/mL of Biotinylated -RBD protein was 430 subsequently added and incubated the plate for 2 hours at room temperature. After washing the plates for three times 431 with PBST, cell supernatants at various dilutions were added to the wells and the plate was further incubated for 1 432 hour at room temperature. Finally, HRP (horseradish peroxidase) conjugated anti-human IgG Fc secondary antibody 433 was added at a dilution of 1:1000 containing 1% BSA and the plate was incubated for an hour at room temperature. 434

After the final wash, TMB substrate (Thermo Fisher Scientific Inc.)) was added and subsequently 1N H2SO4 was 435 added to stop the reaction. The absorption was measured at 450 nm. 436 437

The IgGs representing the mAbs were produced in either HEK 293T (ATCC) or Expi293 (Thermo Scientific) cells. Anti-RBD IgG ELISA was performed essentially as described in Mehdi et al. (Mehdi et al., 2020) . For the screening 453 of donors, plasma samples were three-fold diluted starting from 1:25 and were assessed for the presence of RBD 454 binding IgG antibodies. To determine the mAb concentration in mice sera, a serial dilution of respective purified 455 mAbs with known concentration was run as standard. mAb concentrations in mice sera were calculated for each 456 sample dilution by interpolation of OD values from respective purified antibody dilutions using GraphPad Prism. 457 458

Preliminary screening of heat-inactivated plasma samples obtained from convalescent donors for their neutralization 460 potential were assessed as described in Malladi et al. (Malladi et al., 2021) with slight modification. Briefly, plasma 461 half an hour. Cells were stained with 1:1000 final dilution of LIVE/DEAD fixable aqua dead cell stain 516 (ThermoFisher) in the same buffer for another 15 minutes. HeLa and HeLa-ACE2 cells stained with SARS-CoV-2 517 RBD alone were used as background and positive control separately. The PE mean fluorescence intensity (MFI) was 518 determined from the gate of singlet and live cells and the percentage of ACE2 binding inhibition was calculated by 519 following formula. Epitope binning experiments were performed using Streptavidin (SA) biosensors (Forte´ Bio) and mAbs were binned 541 into epitope specificities. All the incubation steps for binning experiments were performed in 1x PBS. 50-100 nM of 542 biotinylated RBD protein antigens were loaded on streptavidin biosensors to achieve 0.9 to 1.3 nm of wavelength 543 Table S3 . Neutralization potency of THSC20.HVTR04 and THSC20.HVTR26 and their combination against replication competent SARS-CoV-2 live VOCs. Table S4 . Neutralization breadth and potency of THSC20.HVTR04 and THSC20.HVTR26 and their combination against pseudoviruses expressing different SARS-CoV-2 VOC and VOI spike variants. Pseudovirus neutralization assay was carried out in HeLa-ACE2 cell line and neutralization was determined by measuring reduction of luciferase activity. Dose-dependent neutralization of SARS-CoV-2 variants by mAbs and their combination was measured to obtain mAb potencies expressed as µg/mL). 

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi

Neutralizing antibodies for the prevention and treatment of COVID-19

Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

SARS-CoV-2 variants, spike mutations and immune escape

Biophysical properties of the clinical-stage antibody landscape

Elicitation of potent serum neutralizing antibody responses in rabbits by immunization with an HIV-1 clade C trimeric Env derived from an Indian elite neutralizer

Current status of therapeutic monoclonal antibodies against SARS-CoV-2

Appion: an integrated, database-driven pipeline to facilitate EM image processing

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain

Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop

UCSF Chimera--a visualization system for exploratory research and analysis

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity

Effect of Prophylactic Use of Intranasal Oil Formulations in the Hamster Model of COVID-19

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

The biological and clinical significance of emerging SARS-CoV-2 variants

The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses

Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study

Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients

New tools for automated high-resolution cryo-EM structure determination in RELION-3

Potently neutralizing and protective human antibodies against SARS-CoV-2

samples were serially two-fold diluted and mixed with 100 TCID50 of SARS-CoV-2 isolate. The virus-plasma 462 mixture was transferred to Vero E6 monolayer seeded in 96 well plates in triplicate and incubated for 1 hour. The 463 cell monolayer was subsequently washed with serum free media following which fresh complete medium was added. 464The plate was further incubated for 72 hours at 37ºC in a humidified CO2 incubator. Absence of cytopathic effect 465 (CPE) as an indicator of virus neutralization was assessed by observing the cells under a bright field microscope. The 466 dilution at which no CPE was observed was considered as the neutralization titer. 467 468

Pseudoviruses expressing complete SARS-CoV2 spike genes were prepared by transient transfection of HEK293T 470 cells with three plasmids: SARS-CoV2 MLV-gag/pol and MLV-CMV-luciferase plasmids using Fugene 6 (Promega 471 Inc.) as described earlier (Rogers et al., 2020) . After 48-hour post transfection, cell supernatants containing 472 pseudotyped viruses were harvested and frozen at -80°C until further use. Neutralization assay was carried out using 473HeLa-hACE2 cells for the infection of SARS-CoV-2 wild type and variant pseudoviruses. The purified IgGs were 474 serially diluted and incubated with pseudoviruses in a humidified Incubator at 37 0 C. After 1-hour incubation HeLa-475 hACE2 cells were added to the 96-well plates at 10,000 cells/well density. After 48 hours of incubation the luciferase 476 activity was measured by adding Britelite substrate (Perkin Elmer Inc.) according to manufacturer's instruction and 477 RLU obtained using a luminometer (Victor X2, Perkin Elmer Inc). 478 479

The live virus neutralization assay was carried out following protocols as described by Bewley et al. (Bewley et al., 481 2021) . Briefly, IgGs were serially diluted and incubated with indicated SARS-CoV-2 isolates. The virus-IgG 482 mixtures were next added to Vero E6 cells for virus adsorption for one hour. The viral inoculum was removed, and 483 cells were overlaid with carboxymethylcellulose and incubated for 24 hours. Cells were fixed and stained with anti-484 spike RBD antibody (Sino Biologicals) followed by HRP-conjugated anti-rabbit antibody (Invitrogen) and incubated 485with TrueBlue substrate (Sera Care). Finally, plates were washed with sterile MilliQ water, air-dried, and 486 microplaques were quantified by AID iSPOT reader (AID GmbH, Strassberg, Germany). 50% neutralization values 487were calculated with four-parameter logistic regression using GraphPad Prism 7·0 software. 488Cell surface spike binding assay. 489The binding of mAbs to the SARS-CoV-2 spikes expressed on the HEK 293T cell-surface was assessed as described 490previously with some modifications (Rogers et al., 2020) . Briefly, HEK293T cells were transfected with the three 491 plasmids used to generate SARS-CoV-2 pseudovirus (SARS-CoV-2 MLV-gag/pol, MLV-CMV-luciferase and 492 SARS-CoV-2 spike plasmids). After incubation for 36 -48 h at 37 o C, cells were trypsinized and a single cell 493 suspension was prepared which was distributed into 96-well U bottom plates. 3-fold serial dilutions of mAbs starting 494 at 10 µg/ml and up to 0.041 µg/mL were prepared in 50 µl/well and added to the spike expressing as well as un- Inhibition of SARS-CoV-2 RBD binding by mAbs to the cell surface hACE2 was assessed by flow cytometry as 506 described previously with some modifications (Rogers et al., 2020) . Briefly, purified mAbs at 100 µg/mL and 507 biotinylated SARS-CoV-2 RBD were mixed in 100 ul of DPBS in the molar ratio of 4:1 and incubated on ice for 1 508 hour. Parental HeLa and HeLa-ACE2 single cell suspension were prepared by washing cells once with DPBS and 509 then detaching by incubation with DPBS supplemented with 5 mM EDTA. The detached HeLa and HeLa-ACE2 cell 510 suspensions were again washed once and resuspended in FACS buffer (2% FBS and 1 mM EDTA in DPBS). 0.5 511 million Hela-ACE2 cells were added to the test mAb/RBD mixture and then incubated at 4°C for half an hour. 0.5 512 million HeLa and HeLa-ACE2 cells were incubated in separate wells with RBD alone without mAbs for use as 513 background and positive control, respectively. After washing once with FACS buffer, HeLa and HeLa-ACE2 cells 514were resuspended in FACS buffer containing 1 µg/ml streptavidin-PE (BD Biosciences) and incubated for another 515